Intrinsic value of Hologic - HOLX

Previous Close

$44.00

  Intrinsic Value

$6.63

stock screener

  Rating & Target

str. sell

-85%

Previous close

$44.00

 
Intrinsic value

$6.63

 
Up/down potential

-85%

 
Rating

str. sell

*Intrinsic value change (in %) minus stock price change (in %) in the past 12 months.

We calculate the intrinsic value of HOLX stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Shares outstanding, mln

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2017(a)
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046
   2047

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  7.98
  10.50
  9.95
  9.45
  9.01
  8.61
  8.25
  7.92
  7.63
  7.37
  7.13
  6.92
  6.73
  6.55
  6.40
  6.26
  6.13
  6.02
  5.92
  5.83
  5.74
  5.67
  5.60
  5.54
  5.49
  5.44
  5.39
  5.36
  5.32
  5.29
  5.26
Revenue, $m
  3,059
  3,380
  3,717
  4,068
  4,434
  4,816
  5,213
  5,626
  6,056
  6,502
  6,966
  7,447
  7,948
  8,469
  9,011
  9,575
  10,162
  10,774
  11,411
  12,076
  12,770
  13,494
  14,249
  15,039
  15,864
  16,727
  17,630
  18,574
  19,562
  20,596
  21,679
Variable operating expenses, $m
 
  2,698
  2,935
  3,182
  3,440
  3,709
  3,989
  4,280
  4,582
  4,897
  5,223
  5,246
  5,598
  5,965
  6,347
  6,744
  7,158
  7,588
  8,037
  8,506
  8,994
  9,504
  10,036
  10,593
  11,174
  11,782
  12,417
  13,082
  13,778
  14,507
  15,270
Fixed operating expenses, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  1,692
  2,698
  2,935
  3,182
  3,440
  3,709
  3,989
  4,280
  4,582
  4,897
  5,223
  5,246
  5,598
  5,965
  6,347
  6,744
  7,158
  7,588
  8,037
  8,506
  8,994
  9,504
  10,036
  10,593
  11,174
  11,782
  12,417
  13,082
  13,778
  14,507
  15,270
Operating income, $m
  1,367
  682
  782
  886
  994
  1,107
  1,224
  1,346
  1,473
  1,605
  1,742
  2,202
  2,350
  2,504
  2,664
  2,831
  3,005
  3,185
  3,374
  3,570
  3,776
  3,990
  4,213
  4,446
  4,690
  4,946
  5,212
  5,492
  5,784
  6,090
  6,410
EBITDA, $m
  1,817
  1,255
  1,380
  1,510
  1,646
  1,788
  1,936
  2,089
  2,248
  2,414
  2,586
  2,765
  2,951
  3,144
  3,346
  3,555
  3,773
  4,000
  4,237
  4,484
  4,741
  5,010
  5,291
  5,584
  5,890
  6,211
  6,546
  6,896
  7,263
  7,647
  8,049
Interest expense (income), $m
  868
  727
  855
  987
  1,126
  1,271
  1,421
  1,578
  1,741
  1,910
  2,086
  2,269
  2,459
  2,657
  2,862
  3,076
  3,299
  3,530
  3,772
  4,023
  4,285
  4,559
  4,844
  5,143
  5,454
  5,780
  6,120
  6,476
  6,848
  7,238
  7,646
Earnings before tax, $m
  1,231
  -44
  -73
  -102
  -132
  -164
  -197
  -232
  -268
  -305
  -344
  -67
  -109
  -153
  -198
  -245
  -294
  -345
  -398
  -453
  -510
  -569
  -631
  -696
  -764
  -834
  -908
  -984
  -1,065
  -1,149
  -1,237
Tax expense, $m
  475
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  756
  -44
  -73
  -102
  -132
  -164
  -197
  -232
  -268
  -305
  -344
  -67
  -109
  -153
  -198
  -245
  -294
  -345
  -398
  -453
  -510
  -569
  -631
  -696
  -764
  -834
  -908
  -984
  -1,065
  -1,149
  -1,237

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  541
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  7,980
  8,224
  9,043
  9,898
  10,789
  11,718
  12,685
  13,690
  14,734
  15,820
  16,948
  18,120
  19,339
  20,606
  21,925
  23,297
  24,726
  26,214
  27,765
  29,382
  31,070
  32,831
  34,670
  36,592
  38,599
  40,699
  42,894
  45,192
  47,596
  50,112
  52,748
Adjusted assets (=assets-cash), $m
  7,439
  8,224
  9,043
  9,898
  10,789
  11,718
  12,685
  13,690
  14,734
  15,820
  16,948
  18,120
  19,339
  20,606
  21,925
  23,297
  24,726
  26,214
  27,765
  29,382
  31,070
  32,831
  34,670
  36,592
  38,599
  40,699
  42,894
  45,192
  47,596
  50,112
  52,748
Revenue / Adjusted assets
  0.411
  0.411
  0.411
  0.411
  0.411
  0.411
  0.411
  0.411
  0.411
  0.411
  0.411
  0.411
  0.411
  0.411
  0.411
  0.411
  0.411
  0.411
  0.411
  0.411
  0.411
  0.411
  0.411
  0.411
  0.411
  0.411
  0.411
  0.411
  0.411
  0.411
  0.411
Average production assets, $m
  3,169
  3,502
  3,850
  4,214
  4,594
  4,990
  5,401
  5,829
  6,274
  6,736
  7,216
  7,716
  8,234
  8,774
  9,335
  9,920
  10,528
  11,162
  11,822
  12,511
  13,229
  13,979
  14,762
  15,581
  16,435
  17,329
  18,264
  19,242
  20,266
  21,338
  22,460
Working capital, $m
  -387
  247
  271
  297
  324
  352
  381
  411
  442
  475
  508
  544
  580
  618
  658
  699
  742
  786
  833
  882
  932
  985
  1,040
  1,098
  1,158
  1,221
  1,287
  1,356
  1,428
  1,504
  1,583
Total debt, $m
  3,347
  3,300
  3,813
  4,348
  4,906
  5,488
  6,093
  6,722
  7,376
  8,055
  8,761
  9,495
  10,258
  11,052
  11,877
  12,736
  13,630
  14,562
  15,533
  16,545
  17,602
  18,704
  19,856
  21,058
  22,315
  23,629
  25,004
  26,442
  27,947
  29,522
  31,172
Total liabilities, $m
  5,195
  5,148
  5,661
  6,196
  6,754
  7,336
  7,941
  8,570
  9,224
  9,903
  10,609
  11,343
  12,106
  12,900
  13,725
  14,584
  15,478
  16,410
  17,381
  18,393
  19,450
  20,552
  21,704
  22,906
  24,163
  25,477
  26,852
  28,290
  29,795
  31,370
  33,020
Total equity, $m
  2,785
  3,076
  3,382
  3,702
  4,035
  4,383
  4,744
  5,120
  5,511
  5,917
  6,339
  6,777
  7,233
  7,707
  8,200
  8,713
  9,247
  9,804
  10,384
  10,989
  11,620
  12,279
  12,967
  13,685
  14,436
  15,221
  16,043
  16,902
  17,801
  18,742
  19,728
Total liabilities and equity, $m
  7,980
  8,224
  9,043
  9,898
  10,789
  11,719
  12,685
  13,690
  14,735
  15,820
  16,948
  18,120
  19,339
  20,607
  21,925
  23,297
  24,725
  26,214
  27,765
  29,382
  31,070
  32,831
  34,671
  36,591
  38,599
  40,698
  42,895
  45,192
  47,596
  50,112
  52,748
Debt-to-equity ratio
  1.202
  1.070
  1.130
  1.170
  1.220
  1.250
  1.280
  1.310
  1.340
  1.360
  1.380
  1.400
  1.420
  1.430
  1.450
  1.460
  1.470
  1.490
  1.500
  1.510
  1.510
  1.520
  1.530
  1.540
  1.550
  1.550
  1.560
  1.560
  1.570
  1.580
  1.580
Adjusted equity ratio
  0.302
  0.374
  0.374
  0.374
  0.374
  0.374
  0.374
  0.374
  0.374
  0.374
  0.374
  0.374
  0.374
  0.374
  0.374
  0.374
  0.374
  0.374
  0.374
  0.374
  0.374
  0.374
  0.374
  0.374
  0.374
  0.374
  0.374
  0.374
  0.374
  0.374
  0.374

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  756
  -44
  -73
  -102
  -132
  -164
  -197
  -232
  -268
  -305
  -344
  -67
  -109
  -153
  -198
  -245
  -294
  -345
  -398
  -453
  -510
  -569
  -631
  -696
  -764
  -834
  -908
  -984
  -1,065
  -1,149
  -1,237
Depreciation, amort., depletion, $m
  450
  573
  598
  625
  652
  681
  711
  743
  775
  809
  844
  563
  601
  640
  681
  724
  768
  815
  863
  913
  966
  1,020
  1,078
  1,137
  1,200
  1,265
  1,333
  1,405
  1,479
  1,557
  1,639
Funds from operations, $m
  -95
  528
  525
  523
  520
  517
  514
  511
  507
  504
  500
  496
  492
  488
  483
  479
  474
  470
  465
  461
  456
  451
  446
  441
  436
  431
  426
  420
  414
  409
  403
Change in working capital, $m
  -103
  23
  25
  26
  27
  28
  29
  30
  31
  33
  34
  35
  37
  38
  40
  41
  43
  45
  47
  49
  51
  53
  55
  58
  60
  63
  66
  69
  72
  76
  79
Cash from operations, $m
  8
  505
  501
  497
  494
  490
  485
  481
  476
  471
  466
  461
  455
  450
  444
  438
  432
  425
  419
  412
  405
  398
  391
  384
  376
  368
  360
  351
  342
  333
  324
Maintenance CAPEX, $m
  0
  -231
  -256
  -281
  -308
  -335
  -364
  -394
  -425
  -458
  -492
  -527
  -563
  -601
  -640
  -681
  -724
  -768
  -815
  -863
  -913
  -966
  -1,020
  -1,078
  -1,137
  -1,200
  -1,265
  -1,333
  -1,405
  -1,479
  -1,557
New CAPEX, $m
  -108
  -333
  -348
  -364
  -380
  -395
  -412
  -428
  -445
  -462
  -480
  -499
  -519
  -540
  -561
  -584
  -608
  -634
  -660
  -689
  -718
  -750
  -783
  -818
  -855
  -894
  -935
  -978
  -1,024
  -1,072
  -1,122
Cash from investing activities, $m
  286
  -564
  -604
  -645
  -688
  -730
  -776
  -822
  -870
  -920
  -972
  -1,026
  -1,082
  -1,141
  -1,201
  -1,265
  -1,332
  -1,402
  -1,475
  -1,552
  -1,631
  -1,716
  -1,803
  -1,896
  -1,992
  -2,094
  -2,200
  -2,311
  -2,429
  -2,551
  -2,679
Free cash flow, $m
  294
  -60
  -104
  -148
  -194
  -241
  -290
  -341
  -394
  -449
  -506
  -565
  -627
  -691
  -758
  -828
  -901
  -977
  -1,056
  -1,140
  -1,226
  -1,317
  -1,413
  -1,512
  -1,616
  -1,726
  -1,840
  -1,960
  -2,086
  -2,218
  -2,356
Issuance/(repayment) of debt, $m
  -137
  494
  512
  535
  558
  581
  605
  629
  654
  680
  706
  734
  763
  793
  825
  859
  894
  932
  971
  1,013
  1,056
  1,103
  1,151
  1,203
  1,257
  1,314
  1,374
  1,438
  1,505
  1,576
  1,650
Issuance/(repurchase) of shares, $m
  -151
  335
  379
  422
  466
  511
  558
  607
  658
  711
  766
  506
  565
  627
  691
  758
  828
  901
  978
  1,057
  1,141
  1,228
  1,319
  1,415
  1,515
  1,619
  1,729
  1,844
  1,964
  2,090
  2,222
Cash from financing (excl. dividends), $m  
  -309
  829
  891
  957
  1,024
  1,092
  1,163
  1,236
  1,312
  1,391
  1,472
  1,240
  1,328
  1,420
  1,516
  1,617
  1,722
  1,833
  1,949
  2,070
  2,197
  2,331
  2,470
  2,618
  2,772
  2,933
  3,103
  3,282
  3,469
  3,666
  3,872
Total cash flow (excl. dividends), $m
  -8
  770
  788
  809
  830
  851
  873
  895
  918
  942
  966
  674
  701
  729
  758
  789
  822
  856
  892
  930
  971
  1,013
  1,058
  1,105
  1,155
  1,208
  1,263
  1,322
  1,383
  1,448
  1,516
Retained Cash Flow (-), $m
  -642
  -335
  -379
  -422
  -466
  -511
  -558
  -607
  -658
  -711
  -766
  -506
  -565
  -627
  -691
  -758
  -828
  -901
  -978
  -1,057
  -1,141
  -1,228
  -1,319
  -1,415
  -1,515
  -1,619
  -1,729
  -1,844
  -1,964
  -2,090
  -2,222
Prev. year cash balance distribution, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  435
  409
  387
  364
  340
  315
  288
  260
  231
  200
  169
  136
  102
  67
  31
  -6
  -45
  -85
  -127
  -170
  -215
  -261
  -309
  -359
  -412
  -466
  -522
  -581
  -642
  -706
Discount rate, %
 
  9.00
  9.45
  9.92
  10.42
  10.94
  11.49
  12.06
  12.66
  13.30
  13.96
  14.66
  15.39
  16.16
  16.97
  17.82
  18.71
  19.65
  20.63
  21.66
  22.74
  23.88
  25.07
  26.33
  27.64
  29.03
  30.48
  32.00
  33.60
  35.28
  37.05
PV of cash for distribution, $m
 
  399
  341
  292
  245
  202
  164
  130
  100
  75
  54
  37
  24
  15
  7
  3
  0
  -2
  -3
  -3
  -3
  -2
  -2
  -1
  -1
  -1
  0
  0
  0
  0
  0
Current shareholders' claim on cash, %
  100
  97.3
  94.7
  92.1
  89.5
  87.0
  84.6
  82.2
  79.9
  77.6
  75.4
  74.1
  72.7
  71.3
  69.9
  68.4
  67.0
  65.5
  64.1
  62.7
  61.2
  59.8
  58.4
  57.0
  55.6
  54.2
  52.8
  51.5
  50.2
  48.9
  47.6

Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women's health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays. It offers viral load assays for the quantitation of Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus-1 (HIV-1). The Breast Health products include breast imaging and related products and accessories, including digital mammography systems, computer-aided detection (CAD) and breast biopsy guidance systems. The GYN Surgical products include NovaSure Endometrial Ablation System and MyoSure Hysteroscopic Tissue Removal System. The Skeletal Health segment offers Discovery and Horizon X-ray bone densitometers and mini C-arm imaging systems.

FINANCIAL RATIOS  of  Hologic (HOLX)

Valuation Ratios
P/E Ratio 16
Price to Sales 4
Price to Book 4.3
Price to Tangible Book
Price to Cash Flow 1514.1
Price to Free Cash Flow -121.1
Growth Rates
Sales Growth Rate 8%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 9.1%
Cap. Spend. - 3 Yr. Gr. Rate 6.2%
Financial Strength
Quick Ratio 0
Current Ratio 0
LT Debt to Equity 78.8%
Total Debt to Equity 120.2%
Interest Coverage 2
Management Effectiveness
Return On Assets 16.9%
Ret/ On Assets - 3 Yr. Avg. 8.8%
Return On Total Capital 13%
Ret/ On T. Cap. - 3 Yr. Avg. 7%
Return On Equity 30.7%
Return On Equity - 3 Yr. Avg. 17.6%
Asset Turnover 0.4
Profitability Ratios
Gross Margin 53%
Gross Margin - 3 Yr. Avg. 53.7%
EBITDA Margin 83.3%
EBITDA Margin - 3 Yr. Avg. 50.6%
Operating Margin 44.7%
Oper. Margin - 3 Yr. Avg. 26.1%
Pre-Tax Margin 40.2%
Pre-Tax Margin - 3 Yr. Avg. 20.5%
Net Profit Margin 24.7%
Net Profit Margin - 3 Yr. Avg. 13.8%
Effective Tax Rate 38.6%
Eff/ Tax Rate - 3 Yr. Avg. 28.1%
Payout Ratio 0%

HOLX stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the HOLX stock intrinsic value calculation we used $3059 million for the last fiscal year's total revenue generated by Hologic. The default revenue input number comes from 2017 income statement of Hologic. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our HOLX stock valuation model: a) initial revenue growth rate of 10.5% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 9%, whose default value for HOLX is calculated based on our internal credit rating of Hologic, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Hologic.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of HOLX stock the variable cost ratio is equal to 80.8%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for HOLX stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 25.9% for Hologic.

Corporate tax rate of 27% is the nominal tax rate for Hologic. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the HOLX stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for HOLX are equal to 103.6%.

Life of production assets of 13.7 years is the average useful life of capital assets used in Hologic operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for HOLX is equal to 7.3%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $2785 million for Hologic - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 279.298 million for Hologic is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Hologic at the current share price and the inputted number of shares is $12.3 billion.

RELATED COMPANIES Price Int.Val. Rating
GE General Electr 17.35 46.28  str.buy
TMO Thermo Fisher 211.48 70.89  str.sell
DHR Danaher 99.59 56.91  sell
BDX Becton Dickins 231.37 68.37  str.sell
BSX Boston Scienti 27.25 10.23  str.sell
COO Cooper 235.19 190.56  hold
DGX Quest Diagnost 101.49 118.30  buy

COMPANY NEWS

▶ Why Mizuho Securities Upgraded Teva Pharmaceutical to a Buy   [Jan-12-18 09:45AM  Market Realist]
▶ Namal Nawana Elected to Hologic Board of Directors   [Jan-11-18 04:01PM  PR Newswire]
▶ ETFs with exposure to Hologic, Inc. : December 29, 2017   [Dec-29-17 12:08PM  Capital Cube]
▶ ETFs with exposure to Hologic, Inc. : December 18, 2017   [Dec-18-17 03:41PM  Capital Cube]
▶ Six Off the Beaten Path Healthcare Stock Gems   [Dec-09-17 12:00PM  TheStreet.com]
▶ ETFs with exposure to Hologic, Inc. : December 8, 2017   [Dec-08-17 01:00PM  Capital Cube]
▶ ETFs with exposure to Hologic, Inc. : November 28, 2017   [Nov-28-17 12:24PM  Capital Cube]
▶ Hologic tops Street 4Q forecasts   [04:21PM  Associated Press]
▶ Hologic, Inc. to Host Earnings Call   [01:30PM  ACCESSWIRE]
▶ ETFs with exposure to Hologic, Inc. : October 23, 2017   [Oct-23-17 10:41AM  Capital Cube]
▶ Opening Bell, October 2, 2107   [Oct-02-17 09:29AM  CNBC Videos]
▶ ETFs with exposure to Hologic, Inc. : September 28, 2017   [Sep-28-17 10:14AM  Capital Cube]
▶ Western Digital and Hologic skid; Centene, Nordstrom climb   [Sep-13-17 04:43PM  Associated Press]
Financial statements of HOLX
Follow us on:   twitter   twitter   twitter   twitter

ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.